<DOC>
	<DOC>NCT01818752</DOC>
	<brief_summary>This is a Phase 3 multicenter, open-label, randomized study in transplant-ineligible subjects with newly diagnosed multiple myeloma. Subjects are randomized to receive 1 of 2 treatment regimens: Carfilzomib, Melphalan and Prednisone (CMP) or Velcade® (Bortezomib), Melphalan and Prednisone (VMP).</brief_summary>
	<brief_title>Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Newly diagnosed symptomatic multiple myeloma Transplantineligibility Males and females ≥ 18 years of age Left ventricular ejection fraction (LVEF) ≥ 40% Waldenstrom macroglobulinemia Known amyloidosis Plasma cell leukemia POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) Significant neuropathy (Grades ≥ 2) within 14 days prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>